Myelodysplastic syndromes: What a primary care physician needs to know

Disease-a-Month

Volumn 56, Issue 8, 2010, Pages 468-478

  Khan, Awais M ^a   Komrokji, Rami S ^a   Haddad, Rami Y ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; DEFERASIROX; DEFEROXAMINE; ELTROMBOPAG; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LENALIDOMIDE; ROMIPLOSTIM;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; ARTICLE; BLEEDING; BLOOD TRANSFUSION; BONE MARROW BIOPSY; CHROMOSOME 20; CHROMOSOME 5; CHROMOSOME 5Q; CHROMOSOME 7; CHROMOSOME 8; CHRONIC KIDNEY FAILURE; CHRONIC MYELOMONOCYTIC LEUKEMIA; CYTOPENIA; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DISEASE COURSE; DYSPNEA; FATIGUE; GENE DELETION; GINGIVA BLEEDING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; IRON CHELATION; IRON DEFICIENCY; KARYOTYPE; LETHARGY; MYELODYSPLASTIC SYNDROME; NUTRITIONAL DEFICIENCY; PATHOGENESIS; PETECHIA; PHYSICIAN; PRIMARY MEDICAL CARE; PROGNOSIS; REFRACTORY ANEMIA; SIDEROBLASTIC ANEMIA; SURVIVAL TIME; THROMBOCYTOPENIA; AGE; AGED; CLASSIFICATION; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES;

AGE FACTORS; AGED; DIAGNOSIS, DIFFERENTIAL; HUMANS; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS;

EID: 77956055376     PISSN: 00115029     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.disamonth.2010.03.007     Document Type: Article

References (36)

1. Bennett J.M., Komrokji R., Kouides P. The myelodysplastic syndromes. Clinical Oncology 2004, Churchill Livingstone, New York. M.D. Abeloff, J.O. Armitage, J.E. Niederhuber (Eds.).
2. Rollison D.E., Nadia H., Smith M.T., et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-04, using data from the NAACCR and SEER programs. Blood 2008, 112(1):45-52.
3. Ma X., Does M., Raza A., et al. Myelodysplastic syndromes: incidence and survival in the United States. Cancer 2007, 109(8):1536-1542.
4. Rosing J.L., Komrokji R.S., Margolin E., et al. In: Anemia in Elderly Hospitalized Veterans: Prevalence, Causes, and Clinical Impact. Ash Annual Meeting Abstracts 2005, 106(11):3756.
5. Park D.J., Koeffler H.P. Therapy-related myelodysplastic syndromes. Semin Hematol 1996, 33(3):256-273.
6. Darrington D.L., Vose J.M., Anderson J.R., et al. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. J Clin Oncol 1994, 12(12):2527-2534.
7. Stone R.M., Neuberg D., Soiffer R., et al. Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 1994, 12(12):2535-2542.
8. Miller J.S., Arthur D.C., Litz C.E., et al. Myelodysplastic syndrome after autologous bone marrow transplantation: an additional late complication of curative cancer therapy. Blood 1994, 83(12):3780-3786.
9. Geddes A.A., Bowen D.T., Jacobs A. Clonal karyotype abnormalities and clinical progress in the myelodysplastic syndrome. Br J Hæmatol 1990, 76(2):194-202.
10. Epling-Burnette P.K., List A.F. Advancements in the molecular pathogenesis of myelodysplastic syndrome. Curr Opin Hematol 2009, 16(2):70-76.
11. Fenaux P., Morel P., Lai J.L. Cytogenetics of myelodysplastic syndromes. Semin Hematol 1996, 33(2):127-138.
12. Ebert B.L., Jennifer P., Jocelyn B., et al. Identification of RPS14 as the 5Q-syndrome gene by RNA interference screen. Ash Annual Meeting Abstracts 2007, 110(11):1.
13. Guillermo G.-M. Demethylating agents in myeloid malignancies. Curr Opin Oncol 2008, 20(6):705-710.
14. Bennett J.M., Komrokji R.S. The myelodysplastic syndromes: diagnosis, molecular biology and risk assessment. Hematology 2005, 10(suppl 1):258-269.
15. Bennett J.M., Catovsky D., Daniel M.T., et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Hæmatol 1976, 33(4):451-458.
16. Bennett J.M., Catovsky D., Daniel M.T., et al. Proposals for the classification of the myelodysplastic syndromes. Br J Hæmatol 1982, 51(2):189-199.
17. Vardiman J.W., Harris N.L., Brunning R.D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002, 100(7):2292-2302.
18. Komrokji R., Bennett J.M. What is "WHO"?. myelodysplastic syndrome classification and prognosis. ASCO Educ Book 2009, 413-419.
19. Greenberg P., Cox C., Lebeau M.M., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89(6):2079-2088.
20. Hellstrom-Lindberg E. Update on Supportive Care and New Therapies: Immunomodulatory Drugs, Growth Factors and Epigenetic-Acting Agents. Hematology/The Education Program of the American Society of Hematology 2005, American Society of Hematology.
21. Hellstrom-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Hæmatol 1995, 89(1):67-71.
22. Hellstrom-Lindberg E., Gulbrandsen N., Lindberg G., et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 2003, 120(6):1037-1046. Scandinavian MDS Group.
23. Miller K. Erythropoietin, with and without granulocyte-colony stimulating factor (G-CSF), in the treatment of myelodysplastic syndrome (MDS) patients. Leuk Res 1998, 22(suppl 1):S13-S16.
24. Kantarjian H., Giles F., List A., et al. The incidence and impact of thrombocytopenia in myelodysplastic syndromes. Cancer 2007, 109(9):1705-1714.
25. Bussel J.B., Kuter D.J., George J.N., et al. Five hundred and thirty-one, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med 2006, 355(16):1672-1681.
26. Hagop K., Frank G., Peter G., et al. Effect of Romiplostim in patients (pts) with low or intermediate risk myelodysplastic syndrome (MDS) receiving azacytidine. Ash Annual Meeting Abstracts 2008, 112:224.
27. Bussel J.B., Cheng G., Saleh M.N., et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007, 357(22):2237-2247.
28. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009, 10(3):223-232.
29. List A., Kurtin S., Roe D.J., et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005, 352(6):549-557.
30. List A., Dewald G., Bennett J., et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006, 355(14):1456-1465. Myelodysplastic syndrome-003 Study Investigators.
31. Sloand E.M., Wu C.O., Peter G., et al. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol 2008, 26(15):2505-2511.
32. Cutler C.S., Lee S.J., Greenberg P., et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 2004, 104(2):579-585.
33. Guillermo S., Benet N., Esperanza S., et al. Independent Impact of Iron Overload and Transfusion Dependency on Survival and Leukemic Evolution in Patients with Myelodysplastic Syndrome. Annual ASH Meeting Abstracts 2008, 112(11):640.
34. List A.F., Baer M.R., Steensma D., et al. Deferasirox (ICL670; Exjade(R)) reduces Serum Ferritin (SF) and Labile Plasma Iron (LPI) in patients with myelodysplastic syndromes (MDS). ASH Annual Meeting Abstracts 2007, 110(11):1470.
35. Christian R., Sabine B., Dominique V., et al. Positive impact of iron chelation therapy (CT) on survival in regularly transfused MDS patients. A Prospective Analysis by the GFM. Annual ASH Meeting Abstracts 2007, 110(11):249.
36. Bennett J.M. Consensus statement on iron overload in myelodysplastic syndromes. Am J Hematol 2008, 83(11):858-861.